Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04616027 · ClinicalTrials.gov registry record · Phase 1
Study OF PF-06882961 IN Participants With Type 2 Diabetes Mellitus With Varying Degrees OF Renal Impairment AND Participants Without Renal Impairment
A Phase 1 study of Healthy and Diabetes Mellitus, Type 2, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
- 3
- Study locations
NCT04616027 is a Phase 1 study of Healthy and Diabetes Mellitus, Type 2 that has completed, run by Pfizer. The registered enrollment target is 42 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT04616027, a Phase 1 study of Healthy and Diabetes Mellitus, Type 2, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study will characterize the effect of varying degrees of renal impairment on the pharmacokinetics (PK), safety and tolerability of a single oral dose of PF- 06882961 compared with participants with normal renal function.
Conditions Studied
Interventions
- DRUG PF-06882961 20 mg
Study Locations (3)
Florida
- University of Miami Hospital - Miami
- Orlando Clinical Research Center - Orlando
Minnesota
- Prism Research LLC dba Nucleus Network - Saint Paul
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2021-01-13 |
| Est. Completion | 2022-02-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04616027
The ClinicalTrials.gov registry entry for NCT04616027 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which PF-06882961 20 mg is the first listed.
NCT04616027 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT04616027 about?
NCT04616027 is a clinical study titled "Study OF PF-06882961 IN Participants With Type 2 Diabetes Mellitus With Varying Degrees OF Renal Impairment AND Participants Without Renal Impairment". This study will characterize the effect of varying degrees of renal impairment on the pharmacokinetics (PK), safety and tolerability of a single oral dose of PF- 06882961 compared with participants with normal renal function.
What is the current status of trial NCT04616027?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2021-01-13. Estimated completion is 2022-02-18.
What conditions does trial NCT04616027 study?
This clinical trial studies the following conditions: Healthy, Diabetes Mellitus, Type 2, Renal Impairment.
What interventions are being tested in trial NCT04616027?
The interventions under investigation include: PF-06882961 20 mg (DRUG).
Who is sponsoring clinical trial NCT04616027?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04616027 being conducted?
This trial has 3 study locations across Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.